🔗 Share this article

The first new treatments for gonorrhoea in a generation are being described as a "huge turning point" in the fight against superbug strains of the bacteria, according to health experts.

An International Public Health Issue

Cases of gonorrhoea are increasing around the world, with figures suggesting more than 82 million infections per year. Particularly high rates are seen in Africa and nations within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an critical and opportune development in the face of rising global incidence, the spread of superbugs and the very limited therapeutic options currently available.”

Public health authorities are deeply concerned about the increase in drug-resistant strains. The global health body has listed it as a "high-priority threat". Ongoing monitoring found that resistance to primary antibiotics like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Drugs Gain Approval

One new antibiotic, marketed under the name a brand name, was authorized by the American regulatory agency in mid-December for use against gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers hope that focused deployment of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GSK, was also approved in the same week. This treatment, which is employed against UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin stemmed from a unique collaborative effort for medication research. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a major breakthrough in the management of superbug gonorrhoea, which previously has been evolving faster than our drug pipeline.”

Clinical Trial Results and Global Access

According to data published in a major medical journal, the new drug successfully treated the vast majority of cases of the STI. This places it at an equal footing with the typical regimen, which uses two antibiotics. The trial involved hundreds of patients from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its development partnership, the non-profit has the rights to license and sell the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have voiced hope. Access to a single-dose, oral treatment such as this is seen as a "game-changer" for public health efforts. This is deemed crucial to reduce the burden of the infection for patients and to stop the proliferation of extremely resistant gonorrhoea around the world.